| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹764.2 0% | 2,600 | ₹0.95 0% | 2500% |
| 5000% | ₹587 0% | 2,800 | ₹0.1 0% | 3,5000% |
| - | - | 2,900 | ₹0.3 0% | 13,0000% |
| 5000% | ₹425.95 0% | 2,950 | ₹1 -28.57% | 46,7500% |
| 1,2500% | ₹366.1 0% | 3,000 | ₹0.7 -48.14% | 37,5001.35% |
| 5000% | ₹366.8 0% | 3,050 | ₹0.7 0% | 14,0000% |
| 3,2500% | ₹349 0% | 3,100 | ₹0.45 -65.38% | 45,750-3.68% |
| 1,2500% | ₹227 0% | 3,150 | ₹1 -20% | 10,7500% |
| 17,500-2.77% | ₹390 18.18% | 3,200 | ₹0.95 -26.92% | 36,0001.40% |
| 20,0000% | ₹331.9 154.42% | 3,250 | ₹0.55 -21.42% | 17,500-17.64% |
| 41,7500.60% | ₹305 30.23% | 3,300 | ₹1.95 -30.35% | 68,500-3.85% |
| 1,39,5000% | ₹265.1 38.94% | 3,350 | ₹3 -28.57% | 51,250-2.84% |
| 1,84,750-1.33% | ₹206.8 53.01% | 3,400 | ₹3.55 -55.34% | 1,45,7506.97% |
| 73,500-3.60% | ₹160 48.14% | 3,450 | ₹6.5 -60.24% | 39,750-10.16% |
| 1,08,000-10.55% | ₹116 93.17% | 3,500 | ₹13.05 -59.84% | 97,750-8% |
| 76,500-4.67% | ₹79.5 104.1% | 3,550 | ₹28 -52.05% | 57,00061.70% |
| 1,79,750-13.68% | ₹53 167% | 3,600 | ₹51.2 -42.92% | 60,500210.25% |
| 83,00037.75% | ₹33.1 202.28% | 3,650 | ₹83.3 -34.33% | 4,500200% |
| 1,29,50011.63% | ₹22.55 219.85% | 3,700 | ₹154.35 0% | 1,0000% |
| 24,75023.75% | ₹14.9 246.51% | 3,750 | ₹164 -35.93% | 2,00060% |
| 91,000-13.94% | ₹10.4 225% | 3,800 | ₹257.15 0% | 5000% |
| 38,00097.40% | ₹5.25 303.84% | 3,900 | - | - |
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
